Have we turned a Covid-19 corner?
In England, where about one person in 50 have Covid, case numbers are falling
“Whisper it,” said Kat Lay and Tom Whipple in The Times, “but there are – perhaps – signs that it could be safe to press ahead with planning for Christmas.” Surveys suggest that coronavirus in the UK may be in retreat.
In England, where about one person in 50 have Covid, case numbers are falling, largely as a result of a drop of infections among secondary-school children. Scientists have cautioned that this downward trend may just be a temporary effect of half-term.
They’ve also warned that cases are still rising among the over-50s as a result of waning immunity. But with booster jabs dealing with that latter problem, and the prospect of new antiviral treatments on the way, the “mood music is beginning to sound optimistic”.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The antiviral pills could be “game changers”, said Matthew Lesh in The Daily Telegraph. Merck’s drug, molnupiravir, which was licensed last week for use in the UK, reduced hospitalisation by 50% among vulnerable people in trials. Pfizer, meanwhile, announced last week that its new antiviral pill, Paxlovid, which is set to be licensed in the UK early next year, reduces hospitalisation by 89%. With these drugs, and others like them, Covid could become a “treatable, uninteresting, even run-of-the-mill, virus”. The only problem is that the UK has so far secured a very limited supply of these pills.
We can’t afford to drop our guard against Covid yet, said The Guardian. As England’s deputy chief medical officer, Prof Jonathan Van-Tam, warned last week, the pandemic is far from over. Indeed, it’s now raging through Europe again.
The recent decision by Jeremy Farrar to walk out of Sage, the Government’s Scientific Advisory Group for Emergencies, showed that some experts feel strongly that the Government is no longer “following the science”, said Mary Dejevsky in The Independent. They may be right; but many of their previous warnings have proved too alarmist, and their opinions should be just one of many that are taken into account.
Ultimately, it must be left to politicians to decide whether or not to reimpose restrictions. “The pandemic may not be quite on its last legs, but it is a positive development that UK ministers and scientists are returning to their separate tracks.”
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
-
‘The worry is far from fanciful’Instant Opinion Opinion, comment and editorials of the day
-
How are Americans bracing for the end of SNAP?TODAY'S BIG QUESTION Millions depend on supplemental federal food funds that are set to expire this month, as the government shutdown begins to be acutely felt
-
Book review: ‘Joyride: A Memoir’Feature A journalist’s story of how she chased and accomplished her dreams
-
Covid-19 mRNA vaccines could help fight cancerUnder the radar They boost the immune system
-
Is this the end of ultraprocessed foods?Today's Big Question California law and the MAHA movement are on the same track
-
The quest to defy ageingThe Explainer Humanity has fantasised about finding the fountain of youth for millennia. How close are we now?
-
Can TrumpRx really lower drug prices?Today’s Big Question Pfizer’s deal with Trump sent drugmaker stocks higher
-
The new Stratus Covid strain – and why it’s on the riseThe Explainer ‘No evidence’ new variant is more dangerous or that vaccines won’t work against it, say UK health experts
-
RFK Jr. vaccine panel advises restricting MMRV shotSpeed Read The committee voted to restrict access to a childhood vaccine against chickenpox
-
The battle of the weight-loss drugsTalking Point Can Novo Nordisk and Eli Lilly regain their former stock market glory? A lot is riding on next year's pills
-
An insatiable hunger for proteinFeature Americans can't get enough of the macronutrient. But how much do we really need?